Amlodipine/valsartan/hydrochlorothiazide

Drug Profile

Amlodipine/valsartan/hydrochlorothiazide

Alternative Names: Copalia HCT; Dafiro HCT; Exforge HCT; Imprida HCT

Latest Information Update: 07 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Branched-chain amino acids; Dihydropyridines
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 03 Dec 2014 Launched prior to this date for Hypertension in Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Netherlands, Poland, Spain, Switzerland, Australia, Norway, Turkey, Malaysia, Singapore, Thailand and Hong Kong (PO)
  • 01 Dec 2014 First generic equivalent available in USA for Hypertension
  • 04 May 2010 Efficacy and adverse events data from a clinical trial in Hypertension presented at the 25th Annual Scientific Meeting of the American Society of Hypertension (ASH-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top